ARCHIMED to Acquire Esperion for $3.16 Per Share in Cash Deal

Key Facts

ARCHIMED has entered into a definitive agreement to acquire Esperion in an all-cash transaction valued at $1.1 billion, designed to take the company private. Under the terms of the deal, Esperion shareholders will receive $3.16 per share in cash upon closing. In addition to the upfront cash consideration, the agreement includes rights for shareholders to participate in up to $100 million in contingent milestone payments. This structure provides immediate liquidity to investors while offering potential future upside through milestone-based achievements. The acquisition highlights ongoing M&A momentum within the healthcare sector as specialized investment firms seek to consolidate promising assets. This transition to private ownership is expected to provide Esperion with the strategic flexibility needed for its next phase of growth.

Version History